Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Phase 3 topline results for pelacarsen target elevated Lp(a) with CVD, a major unmet need.
What changed
Phase 3 topline results for pelacarsen target elevated Lp(a) with CVD, a major unmet need.
Why it matters
Phase 3 topline results for pelacarsen target elevated Lp(a) with CVD, a major unmet need. — impact context not separately stored; see What changed.
← Dashboard
Sep 04, 2026 09:35 PM ET